Ronald Grane
Phosphoproteomics has been extensively used as a diagnosing analysis tool to characterize the phosphorylated parts of the cancer protein. Advances within the field have yielded insights into new drug targets, mechanisms of sickness progression and drug resistance, and biomarker discovery. However, application of this technology to clinical analysis has been difficult as a result of sensible problems with reference to specimen integrity and neoplasm nonuniformity. On the far side these limitations, phosphoproteomics has the potential to play a polar role in translational studies and contribute to advances in several neoplasm teams, together with rare sickness sites like cancer. During this review, we have a tendency to propose that deploying phosphoproteomic technologies in translational analysis could facilitate the identification of higher outlined prognostic biomarkers for patient stratification, inform drug choice in umbrella trials and determine new combos to beat drug resistance. We offer an summary of current phosphoproteomic technologies, like affinity-based assays and mass spectrometry-based approaches, and discuss their benefits and limitations. We have a tendency to use cancer.
KeywordsPhosphoproteomics; Sarcoma; Signal transduction; Clinical trials; Drug resistance
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi